These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23219766)

  • 41. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of anti-tumor necrosis factor agents.
    Wong JB
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S65-70. PubMed ID: 15552517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biosimilars for the management of rheumatoid arthritis: economic considerations.
    Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
    Stevenson MD; Wailoo AJ; Tosh JC; Hernandez-Alava M; Gibson LA; Stevens JW; Archer RJ; Simpson EL; Hock ES; Young A; Scott DL
    J Rheumatol; 2017 Jul; 44(7):973-980. PubMed ID: 28202743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evolution of cost structures in rheumatoid arthritis over the past decade.
    Huscher D; Mittendorf T; von Hinüber U; Kötter I; Hoese G; Pfäfflin A; Bischoff S; Zink A;
    Ann Rheum Dis; 2015 Apr; 74(4):738-45. PubMed ID: 24406543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health economics: implications for novel antirheumatic therapies.
    Kavanaugh A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv65-9. PubMed ID: 16239392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economics of stratified medicine in rheumatoid arthritis.
    Gavan S; Harrison M; Iglesias C; Barton A; Manca A; Payne K
    Curr Rheumatol Rep; 2014 Dec; 16(12):468. PubMed ID: 25366935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic consequences and potential benefits.
    Fautrel B; Verstappen SM; Boonen A
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):607-24. PubMed ID: 22137927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantifying the economic burden of productivity loss in rheumatoid arthritis.
    Filipovic I; Walker D; Forster F; Curry AS
    Rheumatology (Oxford); 2011 Jun; 50(6):1083-90. PubMed ID: 21245074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Schoels M; Wong J; Scott DL; Zink A; Richards P; Landewé R; Smolen JS; Aletaha D
    Ann Rheum Dis; 2010 Jun; 69(6):995-1003. PubMed ID: 20447950
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
    Tundia N; Kotze PG; Rojas Serrano J; Mendes de Abreu M; Skup M; Macaulay D; Signorovitch J; Chaves L; Chao J; Bao Y
    J Med Econ; 2016 Dec; 19(12):1187-1199. PubMed ID: 27376404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of health economics modelling in rheumatoid arthritis.
    Emery P
    Pharmacoeconomics; 2004; 22(2 Suppl 1):55-69. PubMed ID: 15157004
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacoeconomics of emerging therapies for rheumatoid arthritis. Based on a presentation by Arthur Kavanaugh, MD.
    Am J Manag Care; 1999 Jun; 5(8 Suppl):S483-7; discussion S487-8. PubMed ID: 10538856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.
    Baser O; Ganguli A; Roy S; Xie L; Cifaldi M
    Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic benefits of optimizing anchor therapy for rheumatoid arthritis.
    Fautrel B
    Rheumatology (Oxford); 2012 Jun; 51 Suppl 4():iv21-6. PubMed ID: 22685272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.